This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors

This study has been completed.
Information provided by (Responsible Party):
Amgen Identifier:
First received: October 6, 2004
Last updated: May 13, 2013
Last verified: May 2013
This study will determine the safety and pharmacokinetics of AMG 706 in subjects with advanced solid tumors.

Condition Intervention Phase
Tumors Drug: Anti-angiogenesis Drug: AMG 706 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1, First in Human, Open-Label, Dose Finding Study Evaluating the Safety and Pharmacokinetics of AMG 706 in Subjects With Advanced Solid Tumors

Further study details as provided by Amgen:

Primary Outcome Measures:
  • Dose limiting toxicity [ Time Frame: Cycle 1 ]

Secondary Outcome Measures:
  • Dose selection [ Time Frame: Study completion ]

Enrollment: 71
Study Start Date: July 2003
Study Completion Date: December 2006
Primary Completion Date: February 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AMG 706
AMG 706 QD
Drug: Anti-angiogenesis
Drug: AMG 706


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Inclusion Criteria: Exclusion Criteria:
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00093873

Sponsors and Collaborators
Study Director: MD Amgen
  More Information

Additional Information:
Responsible Party: Amgen Identifier: NCT00093873     History of Changes
Other Study ID Numbers: 20030116
Study First Received: October 6, 2004
Last Updated: May 13, 2013

Keywords provided by Amgen:
Solid Tumors

Additional relevant MeSH terms:
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs processed this record on June 23, 2017